| P2093 | author name string | Jerry R Colca | |
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| | Thiazolidinediones | Q34346862 |
| | The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study | Q34623719 |
| | Enhancing Incretin Action for the Treatment of Type 2 Diabetes | Q35545683 |
| | Rosiglitazone RECORD study: glucose control outcomes at 18 months | Q35987411 |
| | Discontinued drugs in 2005: endocrine and metabolic | Q36715738 |
| | Discontinued drugs in 2006: renal, endocrine and metabolic drugs | Q38460231 |
| | Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice | Q43649896 |
| | Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus | Q44786820 |
| | The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes | Q44995597 |
| | A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 |
| | Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption | Q46592677 |
| | What has prevented the expansion of insulin sensitisers? | Q46965009 |
| | Clinical implications of the DREAM Study. | Q51479715 |
| | Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. | Q53848758 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1735-1739 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | 67 th annual meeting of the American Diabetes Association | |
| P478 | volume | 16 | |